Respinor DXT

DXT, or Diaphragm Excursion Technology, is a ground-breaking non-invasive medical device developed by RESPINOR that utilizes ultrasound for operator-independent, continuous monitoring of the diaphragm, the main breathing muscle, in critically ill patients.
This technology aids in the early detection of diaphragm dysfunction and enhances clinical decision-making in critical care settings.

Clinically proven output

DXT measures diaphragm excursion (DE) and respiratory rate (RR) in real-time including trends. DXT has a well-established cut-off value to detect patients at increased risk of reintubation during the weaning process from MV.

Medical need

By identifying patients at increased risk of extubation failure during the weaning process from mechanical ventilation, RESPINOR DXT has the potential to improve decision making and reduce the number of emergency re-intubations, and potential morbidity associated with mechanical ventilation, as well as ICU and hospital length of stay.

Purpose

‍DXT aims to optimize extubation timing, reduce re-intubation rates, improve patient outcomes, and thereby lower healthcare costs.

Technology

DXT uses sensors with optimized design for patient comfort, continuous monitoring, and computer-aided sensor placement.

Non-invasive

DXT offers a non-invasive solution for monitoring diaphragm function.

Validated technology

Successfully validated in clinical studies on mechanically ventilated patients

Click here to visit their website